Dual Therapy Can Reduce TB Prophylaxis From Nine Months to One: Fewer Side Effects and More People Complete Treatment
New results presented at CROI 2018 from a large international study using a simplified approach to prevent TB have the potential to dramatically improve outcomes for HIV positive people.
A review of the effect of rifampin on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics presented at CROI 2018.
2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...
Low dietary calcium might contribute to low bone mineral density (BMD) in men living with hepatitis C but not in those with HIV, according to a Veterans Administration analysis.
The majority of HIV-positive people with a statin indication by current guidelines are not receiving a statin, according to an analysis at a St. Louis HIV clinic.
HIV.gov shares their conversations with several presenters and participants at USCA 2017 about HIV-related stigma and curing hepatitis C coinfection among people living with HIV.
The findings could inform the debate on the merits of TDF, which is available in many regions as a less-costly generic, versus the more recently approved prodrug tenofovir alafenamide (TAF).
Osteopenia: Zoledronic Acid Has Greater Impact Than Switching From Tenofovir Disoproxil Fumarate Regimens
For HIV-positive men with osteopenia, bisphosphonate therapy with zoledronic acid is more effective at increasing bone mineral density than switching from tenofovir disoproxil fumarate (TDF, Viread).
A 12-year analysis of the large NA-ACCORD cohort showed that more than half of those who could use a statin to treat their cardiovascular diseasehad not received a prescription for it.
The 2017 Synchronicity Conference, a national conference that focuses on HIV and hepatitis C, also addressed LGBT health for the first time this year.